title: No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.
abstract: Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission is unknown. The Mma Bana Study randomized treatment-naive pregnant women with CD4 ≥200 cells per cubic millimeter to receive either abacavir/zidovudine/lamivudine [triple nucleoside reverse transcriptase inhibitor (NRTI) arm] or lopinavir/ritonavir/zidovudine/lamivudine [protease inhibitor (PI) arm]. Drugs were discontinued after 6 months of breastfeeding. One month after discontinuation, 29 NRTI arm samples and 25 PI arm samples were successfully genotyped. No clinically significant antiretroviral resistance mutations were detected. Eight minor resistance mutations were found among 11 (20%) women (3 from NRTI arm and 8 from PI arm), occurring at similar frequencies to those reported in HIV-1 subtype C treatment-naive cohorts.
authors.affiliation: *Botswana-Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana; †Department of Pathology, School of Medicine, University of Botswana, Gaborone, Botswana; ‡Harvard University, Cambridge, MA; §Department of Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA; ‖Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA; ¶Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; and #Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Sajini
authors.initials: S
authors.lastname: Souda
authors.forename: Simani
authors.initials: S
authors.lastname: Gaseitsiwe
authors.forename: Nathan
authors.initials: N
authors.lastname: Georgette
authors.forename: Kathleen
authors.initials: K
authors.lastname: Powis
authors.forename: Daisy
authors.initials: D
authors.lastname: Moremedi
authors.forename: Thato
authors.initials: T
authors.lastname: Iketleng
authors.forename: Jean
authors.initials: J
authors.lastname: Leidner
authors.forename: Claire
authors.initials: C
authors.lastname: Moffat
authors.forename: Anthony
authors.initials: A
authors.lastname: Ogwu
authors.forename: Shahin
authors.initials: S
authors.lastname: Lockman
authors.forename: Sikhulile
authors.initials: S
authors.lastname: Moyo
authors.forename: Mompati
authors.initials: M
authors.lastname: Mmalane
authors.forename: Rosemary
authors.initials: R
authors.lastname: Musonda
authors.forename: Joseph
authors.initials: J
authors.lastname: Makhema
authors.forename: Max
authors.initials: M
authors.lastname: Essex
authors.forename: Roger
authors.initials: R
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D001902:Botswana; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008969:Molecular Sequence Data; D020125:Mutation, Missense; D011247:Pregnancy; D017422:Sequence Analysis, DNA; D028761:Withholding Treatment
chemical_list: D019380:Anti-HIV Agents
references.citation: AIDS. 2007 Aug 20;21(13):1673-82
references.pmid: 17690564
references.citation: Lancet Infect Dis. 2011 Oct;11(10):750-9
references.pmid: 21802367
references.citation: J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):241-7
references.pmid: 21765365
references.citation: N Engl J Med. 2010 Jun 17;362(24):2282-94
references.pmid: 20554983
references.citation: Indian J Med Microbiol. 2008 Apr-Jun;26(2):151-4
references.pmid: 18445952
references.citation: Clin Infect Dis. 2009 Feb 15;48(4):462-72
references.pmid: 19133804
references.citation: AIDS. 2007 May 11;21(8):965-71
references.pmid: 17457090
references.citation: J Clin Virol. 2010 Jul;48(3):162-7
references.pmid: 20427228
references.citation: J Virol Methods. 2010 Feb;163(2):505-8
references.pmid: 19917318
references.citation: AIDS. 2007 Jan 11;21(2):199-205
references.pmid: 17197811
references.citation: N Engl J Med. 2002 Jun 27;346(26):2039-46
references.pmid: 12087139
references.citation: J Infect Dis. 2005 Feb 1;191(3):339-47
references.pmid: 15633092
references.citation: J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400
references.pmid: 17195761
references.citation: J Virol. 2004 Apr;78(8):4234-47
references.pmid: 15047838
references.citation: AIDS. 2001 Jun 15;15(9):F29-40
references.pmid: 11416735
references.citation: Antimicrob Agents Chemother. 1994 Jul;38(7):1541-7
references.pmid: 7979286
references.citation: Antivir Ther. 2002 Mar;7(1):43-51
references.pmid: 12008787
references.citation: AIDS Res Hum Retroviruses. 2007 Jun;23(6):764-8
references.pmid: 17604538
references.citation: J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):216-29
references.pmid: 12045685
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):176-82
references.pmid: 14693537
references.citation: AIDS. 2000 Mar 10;14(4):397-403
references.pmid: 10770542
references.citation: J Infect Dis. 2004 Jan 1;189(1):51-60
references.pmid: 14702153
references.citation: J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40
references.pmid: 19675018
references.citation: AIDS. 2005 Jan 3;19(1):63-7
references.pmid: 15627034
references.citation: J Infect Dis. 2004 Jan 15;189(2):265-72
references.pmid: 14722892
references.citation: PLoS One. 2011;6(5):e20357
references.pmid: 21655245
references.citation: N Engl J Med. 2006 Nov 30;355(22):2283-96
references.pmid: 17135583
references.citation: Lancet. 2006 Jun 17;367(9527):1981-9
references.pmid: 16782488
references.citation: AIDS. 2008 Jul 31;22(12):1417-23
references.pmid: 18614864
references.citation: Antivir Ther. 2008;13(1):135-9
references.pmid: 18389908
references.citation: J Infect Dis. 2010 Apr 1;201(7):1063-71
references.pmid: 20196655
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):522-9
references.pmid: 19502990
references.citation: Clin Infect Dis. 2010 Mar 15;50(6):890-4
references.pmid: 20166821
references.citation: JAMA. 2011 Apr 6;305(13):1327-35
references.pmid: 21467286
references.citation: Lancet. 2002 Apr 6;359(9313):1178-86
references.pmid: 11955535
references.citation: PLoS Med. 2008 Jul 29;5(7):e158
references.pmid: 18666824
references.citation: Antivir Ther. 2004 Feb;9(1):77-84
references.pmid: 15040539
references.citation: AIDS. 2007 Jan 11;21(2):215-23
references.pmid: 17197813
references.citation: N Engl J Med. 2007 Jan 11;356(2):135-47
references.pmid: 17215531
references.citation: AIDS. 2010 Jan 2;24(1):45-53
references.pmid: 19915448
references.citation: AIDS. 2005 Jul 22;19(11):1231-3
references.pmid: 15990579
references.citation: Antivir Chem Chemother. 2005;16(2):103-15
references.pmid: 15889533
references.citation: AIDS. 2003 Jul 4;17(10):1570-2
references.pmid: 12824800
references.citation: Clin Infect Dis. 2009 Jan 15;48(2):239-47
references.pmid: 19086910
references.citation: N Engl J Med. 2004 Apr 29;350(18):1850-61
references.pmid: 15115831
references.citation: AIDS Res Hum Retroviruses. 2008 Jun;24(6):797-804
references.pmid: 18507526
references.citation: J Infect Dev Ctries. 2009 Jun 01;3(5):380-91
references.pmid: 19759509